(ALMDT) Mediantechn - Ratings and Ratios
Software, Platform, Device, Service
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 82.8% |
| Value at Risk 5%th | 105% |
| Relative Tail Risk | -22.79% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.41 |
| Alpha | -22.53 |
| CAGR/Max DD | -0.34 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.478 |
| Beta | 0.490 |
| Beta Downside | 1.138 |
| Drawdowns 3y | |
|---|---|
| Max DD | 86.28% |
| Mean DD | 53.55% |
| Median DD | 55.82% |
Description: ALMDT Mediantechn October 19, 2025
Median Technologies SA (ticker ALMDT) is a French-based developer and marketer of AI-driven medical imaging software, serving markets in France, the United States, Canada, the United Kingdom, China, and other international regions. Founded in 2002 and headquartered in Valbonne, the firm operates within the Health Care Technology sub-industry.
The company’s product suite includes iBiops, an AI-powered software-as-a-medical-device (SaMD) for early detection of cancers and fibrotic diseases; iSee, which provides image-analysis services for clinical-trial sponsors; and iCRO, a platform that sells imaging services for oncology trials. These offerings target both diagnostic workflows and drug-development pipelines, positioning Median at the intersection of precision medicine and clinical-trial efficiency.
Key performance indicators to watch include the annual recurring revenue (ARR) growth rate-historically ~15-20 % YoY-as well as the proportion of revenue derived from the U.S. market, which now exceeds 40 % and serves as a proxy for exposure to the larger FDA-regulated ecosystem. Sector-wide, demand for AI-enabled imaging is being driven by rising oncology trial volumes (global oncology R&D spend grew ~9 % in 2023) and increasing reimbursement pressure for early-diagnosis tools in Europe and North America.
For a deeper quantitative assessment, consider reviewing ValueRay’s analyst notes on ALMDT to gauge how these trends may translate into future valuation metrics.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-48.2m TTM) > 0 and > 6% of Revenue (6% = 2.74m TTM) |
| FCFTA -1.67 (>2.0%) and ΔFCFTA -117.5pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -51.65% (prev 34.42%; Δ -86.06pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -1.57 (>3.0%) and CFO -38.2m > Net Income -48.2m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 0.47 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (18.5m) change vs 12m ago 17.20% (target <= -2.0% for YES) |
| Gross Margin -63.61% (prev -68.75%; Δ 5.14pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 154.5% (prev 68.11%; Δ 86.35pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -7.29 (EBITDA TTM -42.9m / Interest Expense TTM 6.07m) >= 6 (WARN >= 3) |
Altman Z'' -20.23
| (A) -0.97 = (Total Current Assets 20.5m - Total Current Liabilities 44.1m) / Total Assets 24.4m |
| (B) -1.04 = Retained Earnings (Balance) -25.2m / Total Assets 24.4m |
| warn (B) unusual magnitude: -1.04 — check mapping/units |
| (C) -1.50 = EBIT TTM -44.3m / Avg Total Assets 29.6m |
| (D) -0.42 = Book Value of Equity -24.3m / Total Liabilities 58.3m |
| Total Rating: -20.23 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 38.79
| 1. Piotroski 2.0pt |
| 2. FCF Yield -30.21% |
| 3. FCF Margin -89.09% |
| 4. Debt/Equity -0.87 |
| 5. Debt/Ebitda -0.50 |
| 7. RoE 234.6% |
| 8. Rev. Trend 73.02% |
| 9. EPS Trend 26.25% |
What is the price of ALMDT shares?
Over the past week, the price has changed by +2.43%, over one month by +1.12%, over three months by -3.06% and over the past year by -8.26%.
Is ALMDT a buy, sell or hold?
What are the forecasts/targets for the ALMDT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8 | 151.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 2.5 | -21.5% |
ALMDT Fundamental Data Overview December 12, 2025
Market Cap EUR = 113.5m (113.5m EUR * 1.0 EUR.EUR)
P/S = 4.8534
P/B = 252.6595
Beta = 0.486
Revenue TTM = 45.7m EUR
EBIT TTM = -44.3m EUR
EBITDA TTM = -42.9m EUR
Long Term Debt = 8.71m EUR (from longTermDebt, last quarter)
Short Term Debt = 20.5m EUR (from shortTermDebt, last quarter)
Debt = 29.4m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 21.3m EUR (from netDebt column, last quarter)
Enterprise Value = 134.6m EUR (113.5m + Debt 29.4m - CCE 8.29m)
Interest Coverage Ratio = -7.29 (Ebit TTM -44.3m / Interest Expense TTM 6.07m)
FCF Yield = -30.21% (FCF TTM -40.7m / Enterprise Value 134.6m)
FCF Margin = -89.09% (FCF TTM -40.7m / Revenue TTM 45.7m)
Net Margin = -105.6% (Net Income TTM -48.2m / Revenue TTM 45.7m)
Gross Margin = -63.61% ((Revenue TTM 45.7m - Cost of Revenue TTM 74.7m) / Revenue TTM)
Gross Margin QoQ = -108.9% (prev -76.97%)
Tobins Q-Ratio = 5.52 (Enterprise Value 134.6m / Total Assets 24.4m)
Interest Expense / Debt = 8.03% (Interest Expense 2.36m / Debt 29.4m)
Taxrate = -1.02% (negative due to tax credits) (129.0k / -12.7m)
NOPAT = -44.7m (EBIT -44.3m * (1 - -1.02%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 0.47 (Total Current Assets 20.5m / Total Current Liabilities 44.1m)
Debt / Equity = -0.87 (negative equity) (Debt 29.4m / totalStockholderEquity, last quarter -34.0m)
Debt / EBITDA = -0.50 (negative EBITDA) (Net Debt 21.3m / EBITDA -42.9m)
Debt / FCF = -0.52 (negative FCF - burning cash) (Net Debt 21.3m / FCF TTM -40.7m)
Total Stockholder Equity = -20.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -197.9% (out of range, set to none)
RoE = 234.6% (negative equity) (Net Income TTM -48.2m / Total Stockholder Equity -20.6m)
RoCE = 373.8% (negative capital employed) (EBIT -44.3m / Capital Employed (Equity -20.6m + L.T.Debt 8.71m))
RoIC = -1824 % (out of range, set to none) (NOPAT -44.7m / Invested Capital 2.45m)
WACC = 7.88% (E(113.5m)/V(142.9m) * Re(7.82%) + D(29.4m)/V(142.9m) * Rd(8.03%) * (1-Tc(-0.01)))
Discount Rate = 7.82% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 8.26%
Fair Price DCF = unknown (Cash Flow -40.7m)
EPS Correlation: 26.25 | EPS CAGR: -5.41% | SUE: -1.76 | # QB: 0
Revenue Correlation: 73.02 | Revenue CAGR: 26.15% | SUE: 0.00 | # QB: 0
EPS next Year (2026-12-31): EPS=-0.41 | Chg30d=+0.000 | Revisions Net=+2 | Growth EPS=+43.7% | Growth Revenue=+35.7%